David T. Beattie

4.9k total citations
90 papers, 3.5k citations indexed

About

David T. Beattie is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Surgery. According to data from OpenAlex, David T. Beattie has authored 90 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 31 papers in Cellular and Molecular Neuroscience and 18 papers in Surgery. Recurrent topics in David T. Beattie's work include Neuropeptides and Animal Physiology (24 papers), Gastrointestinal motility and disorders (13 papers) and Gastroesophageal reflux and treatments (10 papers). David T. Beattie is often cited by papers focused on Neuropeptides and Animal Physiology (24 papers), Gastrointestinal motility and disorders (13 papers) and Gastroesophageal reflux and treatments (10 papers). David T. Beattie collaborates with scholars based in United States, United Kingdom and China. David T. Beattie's co-authors include John J. Mekalanos, Helen E. Connor, Jacqueline A.M. Smith, Yu‐Cheng Gu, Robert L. Deresiewicz, Andrew Camilli, John M. Clough, Guang‐Fu Yang, Nick Mulholland and Kevin Killeen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Gastroenterology.

In The Last Decade

David T. Beattie

89 papers receiving 3.4k citations

Peers

Countries citing papers authored by David T. Beattie

Since Specialization

Citations

This map shows the geographic impact of David T. Beattie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Beattie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Beattie more than expected).

Fields of papers citing papers by David T. Beattie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Beattie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Beattie. The network helps show where David T. Beattie may publish in the future.

Co-authorship network of co-authors of David T. Beattie

This figure shows the co-authorship network connecting the top 25 collaborators of David T. Beattie. A scholar is included among the top collaborators of David T. Beattie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. Beattie. David T. Beattie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First‐in‐Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease 2024 ·Clinical Pharmacology & Therapeutics ·Julie C. Ullman, Ryan A. Dick, (unknown), Todd Minga, Samnang Tep, Terrence F. Satterfield, Yannan Xi, David T. Beattie, Tonya Marmon, Joel M. Neutel, Brian M. Chung, Janet M. Leeds, Sarah B. Noonberg, Eric M. Green, Harold S. Bernstein	1
2	Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK 2022 ·ACS Medicinal Chemistry Letters ·Frederick W. Goldberg, Attilla Ting, David T. Beattie, Gillian M. Lamont, Charlene Fallan, M. Raymond V. Finlay, Beth Williamson, Marianne Schimpl, Alexander R. Harmer, (unknown), Pär Nordell, Anna Cronin, Mercedes Vázquez–Chantada, Derek Barratt, Antonio Ramos‐Montoya, Elaine Cadogan, Barry R. Davies	7
3	The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor 2019 ·Journal of Medicinal Chemistry ·Frederick W. Goldberg, M. Raymond V. Finlay, Attilla Ting, David T. Beattie, Gillian M. Lamont, Charlene Fallan, Gail L. Wrigley, Marianne Schimpl, Martin Howard, Beth Williamson, Mercedes Vázquez–Chantada, Derek Barratt, Barry R. Davies, Elaine Cadogan, Antonio Ramos‐Montoya, Emma Dean	66
4	Synthesis and antifungal activity of 3-(1,3,4-oxadiazol-5-yl)-indoles and 3-(1,3,4-oxadiazol-5-yl)methyl-indoles 2013 ·European Journal of Medicinal Chemistry ·Ming‐Zhi Zhang, Nick Mulholland, David T. Beattie, Dianne Irwin, Yu‐Cheng Gu, Qiong Chen, Guang‐Fu Yang, John M. Clough	129
5	AZD-3043 2012 ·Anesthesiology ·Talmage D. Egan, Shinju Obara, Thomas E. Jenkins, Sarah Jaw‐Tsai, Shanti M. Amagasu, (unknown), Scott C. Steffensen, David T. Beattie	28
6	Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT4 receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation 2012 ·Bioorganic & Medicinal Chemistry Letters ·Daniel D. Long, Scott R. Armstrong, David T. Beattie, Seok Ki Choi, (unknown), (unknown), (unknown), (unknown), P.P.A. Humphrey, Lan Jiang, Daniel G. Marquess, Jeng‐Pyng Shaw, Jacqueline A.M. Smith, (unknown), Ross G. Vickery	16
7	The Pharmacology of TD-8954, a Potent and Selective 5-HT4 Receptor Agonist with Gastrointestinal Prokinetic Properties 2011 ·Frontiers in Pharmacology ·David T. Beattie, Scott R. Armstrong, Ross G. Vickery, Pamela R. Tsuruda, (unknown), (unknown), (unknown), (unknown), Kathryn Kersey, (unknown), (unknown)	36
8	Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study 2010 ·Alimentary Pharmacology & Therapeutics ·Michael R. Goldberg, Ying Li, John F. Johanson, Allen W. Mangel, Michael M. Kitt, David T. Beattie, Kathryn Kersey, (unknown)	86
9	Synthesis and evaluation of two series of 4′-aza-carbocyclic nucleosides as adenosine A2A receptor agonists 2009 ·Bioorganic & Medicinal Chemistry Letters ·David T. Beattie, (unknown), Zarin Brown, Steven J. Charlton, Brian J. Cox, Robin A. Fairhurst, John R. Fozard, Peter Gedeck, Paul Kirkham, Koremu Meja, Lana Nanson, (unknown), (unknown), Gillian Spooner, Roger Taylor, Robert J. Turner, (unknown), Hannah L. Woodward	9
10	The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity 2008 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·David T. Beattie, Scott R. Armstrong, J P Shaw, Daniel G. Marquess, (unknown), Jacqueline A.M. Smith, J. Andrew Taylor, P.P.A. Humphrey	43
11	A comparison of the pharmacological properties of guinea‐pig and human recombinant 5‐HT₄receptors 2007 ·British Journal of Pharmacology ·R. Vickery, (unknown), Elad Kaufman, David T. Beattie, (unknown), (unknown), P.P.A. Humphrey, Jacqueline A.M. Smith	13
12	Identification of novel staphylococcal virulence genes byin vivoexpression technology 1998 ·Molecular Microbiology ·(unknown), David T. Beattie, Robert L. Deresiewicz	152
13	Attenuation of Fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea-pig 1997 ·Brain Research ·(unknown), (unknown), David T. Beattie	27
14	Baclofen: reduction of presynaptic calcium influx in the cat spinal cord in vivo 1997 ·Experimental Brain Research ·D.R. Curtis, Bruce Gynther, (unknown), David T. Beattie	38
15	GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity 1996 ·Regulatory Peptides ·C. Gardner, Duncan Armour, David T. Beattie, Jeremy D. Gale, A.B. Hawcock, Gavin J. Kilpatrick, D.J. Twissell, P. Ward	122
16	Recent developments in tachykinin NK₁receptor antagonists: prospects for the treatment of migraine headache 1995 ·Canadian Journal of Physiology and Pharmacology ·David T. Beattie, Helen E. Connor, R.M. Hagan	21
17	An in vivo electrophysiological investigation of group Ia afferent fibres and ventral horn terminations in the cat spinal cord 1995 ·Experimental Brain Research ·D.R. Curtis, Bruce Gynther, David T. Beattie, (unknown)	14
18	Development Of A Live, Oral, Attenuated Vaccine Against El Tor Cholera 1994 ·The Journal of Infectious Diseases ·David N. Taylor, Kevin Killeen, (unknown), Julie Kenner, Trinka S. Coster, David T. Beattie, J W Ezzell, (unknown), Andrew F. Trofa, Maria H. Sjögren, Arthur M. Friedlander, John J. Mekalanos, Jerald Sadoff	88
19	Neurokinin‐induced changes in pial artery diameter in the anaesthetized guinea‐pig 1993 ·British Journal of Pharmacology ·David T. Beattie, Carole M. Stubbs, Helen E. Connor, W. Feniuk	25
20	Synthesis and Single Cell Pharmacology of Potential Heterocyclic Bioisosteres of the Excitatory Amino Acid Antagonist Glutamic Acid Diethyl Ester. 1990 ·Acta chemica Scandinavica/Acta chemica Scandinavica. B, Organic chemistry and biochemistry/Acta chemica Scandinavica. A, Physical and inorganic chemistry/Acta chemica Scandinavica. Series B. Organic chemistry and biochemistry/Acta chemica Scandinavica. Series A, Physical and inorganic chemistry ·Ulf Madsen, Elsebet Ø. Nielsen, D.R. Curtis, David T. Beattie, (unknown), Knut Maartmann-Moe, Svante Wold	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact